Two real-time TaqMan PCRs for the detection of Alongshan Virus (ALSV), a new member of the tick-borne Flaviviridae family

This article has been Reviewed by the following groups

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Introduction: Alongshan Virus (ALSV) is a tick-borne Flaviviridae. Ticks carrying ALSV have been identified in various regions, including China, Russia, Finland, Switzerland, and Germany, mainly within Ixodes ricinus and Ixodes persulcatus species. Hypothesis/Gap Statement: However, the clinical relevance and the pathogenicity of ALSV in humans is still unknown. Aim: We aimed to validate and integrate a real-time polymerase chain reaction (PCR) assay on our in-house molecular diagnostic platform to accurately detect ALSV and then further investigate its clinical relevance and its potential role as agent of meningoencephalitis in humans. Methodology: We customized two ALSV-specific Taqman RT-PCR assays targeting the NS3 and NS5 genes to align with the genetic diversity of ALSV sequences and the technical features of TaqMan probes-related technologies. Positive controls included ALSV RNA from infected Swiss ticks and synthetic plasmids including the target region of the RT-PCR assays. Results: To determine the limit of detection of the ALSV PCR assay, we used serial dilutions of the synthetic plasmid. Amplification rates of 100%, 92%, and 20% were respectively achieved for 1000, 100, and 10 copies per reaction for the NS3 PCR and 100%, 100%, 20% for the NS5 PCR. Intra- and inter-run reproducibility, evaluated over five independent runs with plasmid dilutions representing 100 and 10 DNA copies per reaction, met diagnostic standards. The assay exhibited 100% specificity (71/71) when tested against (i) a panel of cerebrospinal fluid pathogens (n=41), including bacteria, viruses, and fungi, and (ii) CSF specimens from our biobank (n=30), collected during winter when local tick exposure is unlikely due to low temperatures. In contrast specific amplification was obtained in ALSV-infected tick samples. Conclusions: Two ALSV real-time PCRs were validated for rapid, sensitive, and specific detection of ALSV RNA. Integration of ALSV PCR into open molecular diagnostic platform such as our, allows for syndromic testing alongside other encephalitis-associated viruses, such as Tick-Borne encephalitis virus or West Nile virus. This PCR will facilitate high-throughput screening of ticks for surveillance purposes. Moreover, this assay could be integrated into other in-house molecular diagnostic platform, in order to accurately detect ALSV to further explore ALSV pathogenic role.

Article activity feed

  1. Comments to Author

    All information seems to be there but some parts require a more in depth explanation, and the methods section slightly restructured so that the findings of the paper are clear. L1 - Use the phrase Taqman PCR assays instead of Taqman PCRs, as that is what has been created here L45 - Here it says amplification rates of 100%, 92% and 20% for 1000, 100 and 10 copies respectively for NS3, but in table 2 it says 100%, 100% and 92% for those copy numbers. L54 - Again use the phrase Taqman PCR assays throughout the whole manuscript L69 - Some more background on named viruses such as single or double stranded, enveloped etc L108-117 - This paragraph could be better structured - i.e. starting with where samples were obtained from and how they were handled and/or treated, with machinery used for each step included, instead of a list of machinery/equipment. L124 - Typo in Thermofisher L131 - Somewhere in the methods section I would suggest including the definition of limit of detection in relation to PCR assays, i.e. lowest concentration of RNA/DNA with 95% positive replicates. Limit of quantification (LOQ) could also be included but is not strictly necessary. LOD and/or LOQ values would be cleared if reported using the copy number - i.e. the LOD for these assays would have to be 100 copies reaction-1 (using the values reported in table 2). Based on those values the true LOD value is likely somewhere between 10 and 100, so a lower LOD value could be achieved if the experiment was run using a narrower range but is not strictly necessary. L167 - As this explains modification of the assay to certain parameters, this needs to be made clearer in the beginning of the manuscript - i.e. why these parameters are used and what advantage that has L173 - this should also be in methods (sequences downloaded from NCBI…) L176 - The LODs for these assays should have a stated definitive value somewhere. L212 - May be worth nothing that many tests on 1 plate is also more cost effective as an additional advantage L253 - If using acronyms I need them to be defined somewhere Figures and tables are clear and communicate their message well

    Please rate the manuscript for methodological rigour

    Good

    Please rate the quality of the presentation and structure of the manuscript

    Satisfactory

    To what extent are the conclusions supported by the data?

    Strongly support

    Do you have any concerns of possible image manipulation, plagiarism or any other unethical practices?

    No

    Is there a potential financial or other conflict of interest between yourself and the author(s)?

    No

    If this manuscript involves human and/or animal work, have the subjects been treated in an ethical manner and the authors complied with the appropriate guidelines?

    Yes

  2. Thank you for submitting your manuscript for publication in Access Microbiology. It has been examined by expert reviewers who have concluded that the work is of potential interest to the readership of Access Microbiology. However, based on the comments received, it is clear that a major revision of this manuscript will be required before a decision can be made on its publication. I will be pleased to consider a revised manuscript along with a document including a point by point response to each of the reviewers comments. Your revised manuscript may be returned to one or more of the original reviewers, along with your itemised response to the reviewers’ comments.

  3. Comments to Author

    The manuscript describes the development of two new RT-qPCR assays for the detection of Alongshan Virus (ALSV). Overall, the methods and results appear to be scientifically sound. However, a lot of information and details are missing. The manuscript is difficult to follow and would benefit from a clearer structure. There are also inconsistencies in the used terminology. Please see below for specific comments. Abstract L33: Why is it important to develop and validate new RT-qPCR assays? L36-37: The aim of the manuscript is to develop new RT-qPCR assays for Alongshan Virus (ALSV). While the role of ALSV in meningoencephalitis in humans is not investigated in this manuscript, rapid and precise diagnostics of ALSV will help to further understand the role the virus plays in meningoencephalitis. L38-42: More details in the Methodology section. L40: What technical features? L54: Replace "real-time PCRs" with RT-qPCR assays. L55: Remove "such as ours." L57: Replace "This PCR" with "these assays." Introduction A paragraph describing Alongshan Virus (ALSV) is missing. Please add several sentences including RNA (negative or positive strand) virus, genome size, composition, genetic diversity of the virus, information on the two targets (NS3 and NS5 genes). L71: Abbreviation for TBEV (Tick-borne encephalitis virus) needs to be mentioned in the text. L72-73: Remove "by the same group." L80: Be consistent with abbreviations for TBEV. L100: Remove "this article" and replace with "this study described." L101: ALSV RT-qPCR assay development. Material and Methods Methods are hard to follow. Change the order to follow a similar structure: sample acquisition, handling and nucleic acid extraction, quality control, primer design, assay validation (assay specificity, sensitivity, and efficiency), data analysis. Important information on assay validation is missing. Please see below for specific comments. L108: It seems like RT-PCR and real-time PCR have been used interchangeably throughout the manuscript resulting in misleading use of acronyms. I would advise using RT-qPCR for reverse transcription quantitative real-time PCR. L110: Which kit was used for extraction on MagNA Pure 96? Small viral kit? L114: Hold stage = reverse transcription? L115: Remove "PCR stage." L116: Provide data on annealing temperature optimization. L116: How many replicates per sample? L125: What is the final reaction volume: 20 or 25 µL? Please clarify. L125-126: Why were NS3 and NS5 genes selected for the RT-qPCR assay? Are those conservative regions? L127-128: Data on optimization of primer and probe concentrations is missing. L132: Standard curve is missing from Results. L151-152: Was there an opportunity to sequence the PCR product to confirm assay specificity? L157: It is unclear how one-way ANOVA was used, please clarify. Results L168: LNA = Locked Nucleic Acid? Is increased Tm needed to run the assays in combination with other assays for screening different pathogens? L173-174: Primer design needs to be moved to Methods. Provide more details like how many sequences were downloaded and used, what program was selected for primer design, etc. Any in silico testing of the assays? L177: How many replicates were used to determine the Limits of Detection? Report also efficiency and slope. L186: "Both PCRs" do you mean assays? Change throughout the text. L194: Replace "our region" with the actual location. L195: 71 samples should be mentioned in Methods. L200: What is meant under PCRs here? The newly developed RT-qPCR assays? L200-201: How many samples were tested? L212: Provide information on the automated system in Methods (instead of listing equipment in the RT-PCR platform, instruments, and program). L218: The last sentence needs a reference. L225-226: Was the main goal to develop an assay that has the same annealing temperature as the rest of the pathogen targets tested in the lab? Multiplexing is crucial in clinical settings to generate fast results, however, this needs to be clearly outlined. Was multiplexing an option? L227: 384 plate instead of 348? L228: Give more information on primer design and in silico testing in Methods and Results. L230: "Observed genes target polymorphism" please elaborate and provide more information in Introduction. L231: Not PCRs but assays. L231-233: Re-write the sentence. L231-235: Repeating Results. L241: Have you tried to multiplex NS5 and NS3 assays? L255-256: How does the study highlight the value of automated molecular diagnostic platforms? L268: In Vitro Diagnostic Regulation (IVDR) and the In Vitro Diagnostic Medical Device Ordinance (IVDO). Table 1: Tm should be the annealing temperature that was used, not of each primer separately. Is the length provided in the table the fragment size? Were plasmids ordered as RNA? Table 2: Provide the number of replicates. Figure 2: Please add sample size and graphs with standard curves for each assay.

    Please rate the manuscript for methodological rigour

    Good

    Please rate the quality of the presentation and structure of the manuscript

    Satisfactory

    To what extent are the conclusions supported by the data?

    Partially support

    Do you have any concerns of possible image manipulation, plagiarism or any other unethical practices?

    No

    Is there a potential financial or other conflict of interest between yourself and the author(s)?

    No

    If this manuscript involves human and/or animal work, have the subjects been treated in an ethical manner and the authors complied with the appropriate guidelines?

    Yes